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Introduction
A healthy immune system depends on highly reactive cells that are able to distinguish foreign antigens from self antigens [1] [2] [3] [4] . Dominant self-tolerance in the periphery is an active process mediated by cells collectively described as having regulatory function. FOXP3 expressing T regulatory cells (Tregs) are critical mediators of dominant self-tolerance. The essential role for these cells in preventing autoimmunity and maintaining immune homeostasis is demonstrated by loss of Treg cells as a result of FOXP3 mutation, which is lethal in both humans and mice 5 . Breakdown of the balance of reactivity and self tolerance in the immune system is believed to lead to a wide variety of autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis, many of which cause progressive and irreversible multi-organ damage [6] [7] [8] [9] .
Tregs are phenotypically defined by their expression of cell surface markers CD4 and CD25, low expression of the IL-7 receptor (CD127) 10 , and expression of the transcription factor Although currently the benchmark for assay of in vitro suppressor function, the MLR has some drawbacks. Three cell populations are required for the MLR assay: effector cells, irradiated 'feeder' cells, and T regulatory cells. This introduces assay variability due to donor specific differences in effector cell proliferation and response to stimulation, as well as variation in feeder cell function post-irradiation. These factors make MLR assays difficult to standardise, which is necessary for investigating Treg function in clinical settings.
Additionally, small variations in assay parameters can be amplified by the 3-6 day culture period.
In order to improve the robustness and application of suppressor assays we have investigated the use of CD154 as a reporter of suppressor function. CD154 (CD40L) is a member of the tumour necrosis factor family 27 . This transmembrane protein is one of the first surface proteins up-regulated on T cells in response to stimulus [28] [29] [30] 
Mixed lymphocyte assay: 5,6-carboxy fluorescein diacetate succinimidyl ester (CFSE)
Cell division of effector cells in a mixed lymphocyte reaction was also analysed by CFSE dilution 33 . Effector CD4 + CD25 -cells were isolated as described above, and labelled with 1M CFSE (Invitrogen, Carlsbad, CA) in PBS for 10 minutes at 37C. 
Karpas-299 cell line
The Karpas-299 cell line, an anaplastic large T cell lymphoma cell line with regulatory T cell-like properties 34 was used as a substitute regulatory T cell in suppressor assays. This cell line was purchased from HPA Culture collections (Porton Down, UK) and cultured in RPMI supplemented with 2mM Glutamine and 10% FCS. When used in suppressor assays,
Teffector:Karpas-299 dilutions from 1:1 to 16:1 were tested.
Generation of iTregs from naive cord blood CD4 + CD25 -T effector cells
To generate iTreg in vitro, CD4 + CD25 -T cells were isolated from cord blood CBMCs using the Invitrogen Dynal Bead Regulatory T cell isolation kit (Invitrogen) and cultured for 7 days in complete X-VIVO 15 supplemented with CD3/CD28 beads (3:1 bead to cell ratio), 500U/mL IL-2, 5ng/mL TGF-β and 10nM all-trans-retinoic acid (ATRA) (Sigma). At day 7, CD3/CD28 beads were removed and cells were allowed to rest for a further 7 days in complete X-VIVO 15 media with 100U/mL IL-2, followed by cryopreservation. Phenotyping of iTregs showed robust expression of FOXP3 and heterogeneous CD25 expression. Induced
Treg populations were thawed and rested overnight in complete RPMI before use in assays. 
Calculation of % Suppression:
Percentage suppression was calculated for each assay using the formulae shown below. 
Results

Ex vivo CB Tregs express CD25 and FOXP3 following expansion.
Cord blood Tregs expanded for 7 days with CD3/CD28 beads, followed by a further 7 day rest period in the absence of expansion beads, expressed high levels of CD25 and FOXP3
(figure 1a,b)(n=8). The addition of a 7 day 'rest' period post-expansion resulted in a reduction in Treg proliferation, rendering these cells suitable to be included in thymidine incorporation assays (figure 1c).
Expanded CB Tregs can suppress induction of CD154 on stimulated CD4 + CD25 -cells
We first demonstrated that cell surface staining with CD4 and CD25 antibodies allowed for 4 ). These data suggests that the CD154 assay is sufficiently sensitive to be used with rare
Comparing CD154 assay measurement of suppressive function with benchmark MLR assays
Treg populations from peripheral blood, enabling its application to clinical cohort studies.
CD154 assay enables measurement of suppressive function in T cell lines
Large We have confirmed that Treg mediated suppression of CD154 expression correlates with suppression of proliferative activity by comparing the assay against CFSE and thymidine based MLR assays using donor matched CB Tregs. In this comparison, the suppressive functional readout by CD154 assay was equivalent to the degree of suppression observed with the MLR assays, indicating that the short assay correlates with the longer term proliferation results. (3) 
